N. prodotti: 0
Totale ordine: € 0,00
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236
Valentina CORRADI 1, 2, Fiorella GASTALDON 1, Carlotta CAPRARA 2, Anna GIULIANI 1, Francesca MARTINO 1, Fiorenza FERRARI 2, Claudio RONCO 1, 2
1 Department of Nephrology, Dialysis & Transplantation, San Bortolo Hospital, Vicenza, Italy; 2 International Renal Research Institute (IRRIV), San Bortolo Hospital, Vicenza, Italy
INTRODUCTION: Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common genetic diseases with a reported prevalence of 1:400 to 1:1000. Since the intact kidneys can compensate for the loss of glomerular filtration in ADPKD patients, renal insufficiency usually remains undetected until almost the fourth decade of life. Hereafter, reliable diagnostic and prognostic biomarkers to identify ADPKD progression are urgently needed. Several studies and systematic reviews tried to identify markers or predictors of rapid disease progression of ADPKD. The aim of this study is to review predictors of rapid disease progression of ADPKD that can be useful to the clinician.
EVIDENCE ACQUISITION: We will describe several factors associated with rapid progression of ADPKD derived from retrospective or cross-sectional studies, suggesting the best and most useful predictors that may help to patients management in clinical practice. We will attempt to identify the most useful predictors of rapid disease progression of ADPKD: established TKV growth rate > 5% per year, annual eGFR decline > 5 ml/min/1.73 m2, truncating PKD1 mutations and elevated plasma copeptin level.
EVIDENCE SYNTHESIS AND CONCLUSIONS: The combination of several factors that can predict the rapid ADPKD progression is more accurate than a single-marker strategy. The “PRO-PKD” risk scoring system combined with TKV, can be useful in order to evaluate the ADPKD patients and they appear to be appropriate predictors of progression disease. Moreover levels of copeptin and some urinary markers can be matched to these factors for improved patient assessment in rapid progression.